Literature DB >> 11579465

Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma.

P Le Baccon1, D Leroux, C Dascalescu, S Duley, D Marais, E Esmenjaud, J J Sotto, M Callanan.   

Abstract

1q rearrangement is a remarkably frequent secondary chromosomal change in both non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), where it is associated with tumor progression. To gain insight into 1q rearrangement-associated disease mechanisms, we used fluorescence in situ hybridization (FISH) to search for recurring 1q breaks in 35 lymphoma samples (31 NHL patients and 4 lymphoma-derived cell lines) as well as 22 MM patients with cytogenetically determined 1q abnormalities. Strikingly, dual-color FISH analysis with chromosome 1 centromere and 1q12-specific probes identified constitutive heterochromatin band 1q12 as the single most frequent breakpoint site in both NHL and MM (39% and 89% of 1q breaks, respectively). These rearrangements consistently generated aberrant heterochromatin/euchromatin junctions and gain of 1q12 material. A further 30% of NHL 1q breaks specifically involved two other novel, closely spaced sites (clusters I and II) within a 2.5 Mb region of proximal 1q21 (D1S3620 to D1S3623). A possible association between these sites and NHL subtype was evident; the cluster I rearrangement was frequent in follicular and diffuse large cell lymphoma, whereas the cluster II rearrangement was more frequently observed in diffuse small-cell lymphoma (2/2 marginal zone lymphomas, 1/2 atypical chronic lymphocytic leukemias, and 1 lymphoplasmacytic lymphoma in this series). Candidate oncogenes bordering this interval (BCL9 and AF1Q) were not rearranged in any patient except one (AF1Q). This study provides the first evidence of involvement of 1q12 constitutive heterochromatin in the pathogenesis of NHL and MM and indicates proximal 1q21 to be of specific pathological significance in NHL. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579465     DOI: 10.1002/gcc.1189

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  The unbalanced chromosomal translocation der(15)t(1;15)(q21;p13) in multiple myeloma.

Authors:  Sonoko Nakano; Kyoko Namura; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Masashi Okamoto; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Detection of microvesicle miRNA expression in ALL subtypes and analysis of their functional roles.

Authors:  Wen-Ying Li; Xiao-Mei Chen; Wei Xiong; Dong-Mei Guo; Li Lu; Hui-Yu Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

4.  A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.

Authors:  Anair Graciela Lema Fernandez; Barbara Crescenzi; Valentina Pierini; Valeria Di Battista; Gianluca Barba; Fabrizia Pellanera; Danika Di Giacomo; Giovanni Roti; Rocco Piazza; Emmalee R Adelman; Maria E Figueroa; Cristina Mecucci
Journal:  Leukemia       Date:  2019-03-28       Impact factor: 11.528

5.  C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma.

Authors:  Sai-Qun Luo; De-Hui Xiong; Jiang Li; Guangdi Li; Yali Wang; Jia-Ming Zhang; Xiu-Fen Bu; Wei-Xin Hu; Jingping Hu
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

6.  Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.

Authors:  Daisy Alapat; Jean Coviello-Malle; Rebecca Owens; Pingping Qu; Bart Barlogie; John D Shaughnessy; Robert B Lorsbach
Journal:  Am J Clin Pathol       Date:  2012-01       Impact factor: 2.493

7.  AF1q/MLLT11 regulates the emergence of human prothymocytes through cooperative interaction with the Notch signaling pathway.

Authors:  Aude Parcelier; Nesrine Maharzi; Marc Delord; Macarena Robledo-Sarmiento; Elisabeth Nelson; Halima Belakhdar-Mekid; Marika Pla; Klaudia Kuranda; Veronique Parietti; Michele Goodhardt; Nicolas Legrand; Irwin D Bernstein; Jean Claude Gluckman; François Sigaux; Bruno Canque
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

8.  CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Authors:  Fenghuang Zhan; Simona Colla; Xiaosong Wu; Bangzheng Chen; James P Stewart; W Michael Kuehl; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

9.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Authors:  Michel Jourdan; Jean-Luc Veyrune; John De Vos; Nicole Redal; Guilhem Couderc; Bernard Klein
Journal:  Oncogene       Date:  2003-05-15       Impact factor: 9.867

10.  BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Authors:  Mala Mani; Daniel E Carrasco; Yunyu Zhang; Kohichi Takada; Moshe E Gatt; Jui Dutta-Simmons; Hiroshi Ikeda; Felipe Diaz-Griffero; Victor Pena-Cruz; Monica Bertagnolli; Lois L Myeroff; Sanford D Markowitz; Kenneth C Anderson; Daniel R Carrasco
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.